Molecular Partners AG (MOLN), a clinical-stage biotechnology firm, is seeking emergency use authorization from the US FDA for ensovibep, a designed ankyrin repeat protein (DARPin)…
November 27, 2024
Molecular Partners AG (MOLN), a clinical-stage biotechnology firm, is seeking emergency use authorization from the US FDA for ensovibep, a designed ankyrin repeat protein (DARPin)…